Results 91 to 100 of about 3,896,424 (394)

DrugRep: an automatic virtual screening server for drug repurposing

Acta Pharmacologica Sinica, 2022
Computationally identifying new targets for existing drugs has drawn much attention in drug repurposing due to its advantages over de novo drugs, including low risk, low costs, and rapid pace.
Jian-Hong Gan, Ji-Xiang Liu, Yang Liu, Shu-wen Chen, Wen-tao Dai, Zhixiong Xiao, Yang Cao   +6 more
semanticscholar   +1 more source

Repurposing of approved cardiovascular drugs [PDF]

Journal of Translational Medicine, 2016
Research and development of new drugs requires both long time and high costs, whereas safety and tolerability profiles make the success rate of approval very low. Drug repurposing, applying known drugs and compounds to new indications, has been noted recently as a cost-effective and time-unconsuming way in developing new drugs, because they have ...
Junichi Ishida, Masaaki Konishi, Nicole Ebner, Jochen Springer   +3 more
openaire   +3 more sources

Multivalent Protein Nanorings for Broad and Potent SARS‐CoV‐2 Neutralization

Advanced Healthcare Materials, EarlyView.
A protein‐only, modular multivalent nanoscaffold displaying 20 anchor points, decorated with two different binders (10 of each), targeting the SARS‐CoV‐2 receptor‐binding domain is presented. The construct self‐assembles into stable, biocompatible, homogeneous nanoparticles, exhibit synergistic binding with fM IC50 values. It also detects spike at 9 ng 
Molood Behbahanipour, Carla Goldin, Cecilia Arahi Prato, Ana Luz Paletta, Oriol Bárcenas, Susanna Navarro, Jordi Pujols, Daniel H. Murgida, María Virginia Tribulatti, Sebastián Esperante, Damian Alvarez‐Paggi, Salvador Ventura   +11 more
wiley   +1 more source

Protein sequence analysis in the context of drug repurposing

BMC Medical Informatics and Decision Making
Motivation Drug repurposing speeds up the development of new treatments, being less costly, risky, and time consuming than de novo drug discovery. There are numerous biological elements that contribute to the development of diseases and, as a result, to ...
Natalia García Sánchez, Esther Ugarte Carro, Lucía Prieto-Santamaría, Alejandro Rodríguez-González   +3 more
doaj   +1 more source

Identification of New Drug Candidates Against \u3cem\u3eBorrelia burgdorferi\u3c/em\u3e Using High-Throughput Screening [PDF]

, 2016
Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that .300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of
Babar, Mustafeez Mujtaba, Inayathullah, Mohammed, Kim, K. M., Parekh, Mansi B., Pothineni, Venkata Raveendra, Rajadas, Jayakumar, Samineni, A. V., Solow-Cordero, David, Tayebi, Lobat, Wagh, Dhananjay   +9 more
core   +3 more sources

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Trends in drug repurposing for chronic hepatitis-B infection: Bibliometric-based approach 1990-2024 [PDF]

BIO Web of Conferences
Chronic hepatitis B (CHB) infection is still a world problem today, especially in the developing countries. Until now, treatment related to CHB is still being continuously pursued using a variety of the latest approaches.
Irham Lalu Muhammad, Amukti Danang Prasetyaning, Adikusuma Wirawan, Singh Dilpreet, Chong Rockie, Pranata Satriya, Khairi Sabiah   +6 more
doaj   +1 more source

KCa 3.1-a microglial target ready for drug repurposing? [PDF]

, 2016
Over the past decade, glial cells have attracted attention for harboring unexploited targets for drug discovery. Several glial targets have attracted de novo drug discovery programs, as highlighted in this GLIA Special Issue.
Dale, E, Eder, C, Möller, T, Staal, RGW
core   +1 more source

Computational Drug Repurposing: Current Trends

Current Medicinal Chemistry, 2019
: Biomedical discovery has been reshaped upon the exploding digitization of data which can be retrieved from a number of sources, ranging from clinical pharmacology to cheminformatics-driven databases. Now, supercomputing platforms and publicly available resources such as biological, physicochemical, and clinical data, can all be integrated to ...
Karaman, Berin, Sippl, Wolfgang
openaire   +2 more sources

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

Advanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement, Jana Ismail, Josefine Schroeder, Amod Godbole, Johanna Schreiber, Christine Weber, Zoltan Cseresnyes, Marc T. Figge, Bettina Löffler, Ulrich S. Schubert, Stephanie Schubert, Christina Ehrhardt, Carsten Hoffmann   +12 more
wiley   +1 more source